| Crohn’s disease G Roda, S Chien Ng, PG Kotze, M Argollo, R Panaccione, A Spinelli, ... Nature Reviews Disease Primers 6 (1), 22, 2020 | 666 | 2020 |
| Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn’s disease or ulcerative colitis: a systematic review and meta … L Peyrin-Biroulet, S Danese, M Argollo, L Pouillon, S Peppas, ... Clinical Gastroenterology and Hepatology 17 (5), 838-846. e2, 2019 | 138 | 2019 |
| Comorbidities in inflammatory bowel disease: a call for action M Argollo, D Gilardi, C Peyrin-Biroulet, JF Chabot, L Peyrin-Biroulet, ... The lancet Gastroenterology & hepatology 4 (8), 643-654, 2019 | 137 | 2019 |
| JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? S Danese, M Argollo, C Le Berre, L Peyrin-Biroulet Gut 68 (10), 1893-1899, 2019 | 122 | 2019 |
| Accuracy of humanitas ultrasound criteria in assessing disease activity and severity in ulcerative colitis: a prospective study M Allocca, G Fiorino, S Bonovas, F Furfaro, D Gilardi, M Argollo, ... Journal of Crohn's and Colitis 12 (12), 1385-1391, 2018 | 115 | 2018 |
| Novel therapeutic targets for inflammatory bowel disease M Argollo, G Fiorino, P Hindryckx, L Peyrin-Biroulet, S Danese Journal of autoimmunity 85, 103-116, 2017 | 115 | 2017 |
| Comparative accuracy of bowel ultrasound versus magnetic resonance enterography in combination with colonoscopy in assessing Crohn’s disease and guiding clinical decision-making M Allocca, G Fiorino, C Bonifacio, F Furfaro, D Gilardi, M Argollo, ... Journal of Crohn's and Colitis 12 (11), 1280-1287, 2018 | 100 | 2018 |
| Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? M Argollo, PG Kotze, P Kakkadasam, G D’Haens Nature Reviews Gastroenterology & Hepatology 17 (11), 702-710, 2020 | 63 | 2020 |
| Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar‐treated IBD patients L Pouillon, S Danese, A Hart, G Fiorino, M Argollo, C Selmi, ... Alimentary Pharmacology & Therapeutics 49 (9), 1181-1187, 2019 | 53 | 2019 |
| Histological healing: should it be considered as a new outcome for ulcerative colitis? A Dal Buono, G Roda, M Argollo, L Peyrin-Biroulet, S Danese Expert Opinion on Biological Therapy 20 (4), 407-412, 2020 | 29 | 2020 |
| Biosimilars of adalimumab: the upcoming challenge in IBD G Fiorino, D Gilardi, C Correale, F Furfaro, G Roda, L Loy, M Argollo, ... Expert Opinion on Biological Therapy 19 (10), 1023-1030, 2019 | 27 | 2019 |
| Modulation of sphingosine-1-phosphate in ulcerative colitis M Argollo, F Furfaro, D Gilardi, G Roda, M Allocca, L Peyrin-Biroulet, ... Expert Opinion on Biological Therapy 20 (4), 413-420, 2020 | 26 | 2020 |
| The impact of biologics in surgical outcomes in ulcerative colitis MC Argollo, PG Kotze, A Spinelli, TNF Gomes, S Danese Best Practice & Research Clinical Gastroenterology 32, 79-87, 2018 | 24 | 2018 |
| Treat to target or ‘treat to clear’in inflammatory bowel diseases: one step further? A Dal Buono, G Roda, M Argollo, E Zacharopoulou, L Peyrin-Biroulet, ... Expert Review of Gastroenterology & Hepatology 14 (9), 807-817, 2020 | 21 | 2020 |
| Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: results of a workshop from the NOCE-BIO consensus group F D’amico, L Pouillon, M Argollo, A Hart, G Fiorino, E Vegni, S Radice, ... Digestive and Liver Disease 52 (2), 138-142, 2020 | 21 | 2020 |
| JAK selectivity: more precision less troubles G Roda, A Dal Buono, M Argollo, S Danese Expert Review of Gastroenterology & Hepatology 14 (9), 789-796, 2020 | 19 | 2020 |
| Interleukin-23 blockers: born to be first-line biologic agents in inflammatory bowel disease? MC Argollo, M Allocca, F Furfaro, L Peyrin-Biroulet, S Danese Current pharmaceutical design 25 (1), 25-31, 2019 | 16 | 2019 |
| TL1A: a new potential target in the treatment of inflammatory bowel disease F Furfaro, L Alfarone, D Gilardi, C Correale, M Allocca, G Fiorino, ... Current Drug Targets 22 (7), 760-769, 2021 | 15 | 2021 |
| Clinical and demographic profile of inflammatory bowel disease patients in a reference center of São Paulo, Brazil TNF Gomes, FS Azevedo, M Argollo, SJ Miszputen, O Ambrogini Jr Clinical and experimental gastroenterology, 91-102, 2021 | 14 | 2021 |
| Vedolizumab for the treatment of Crohn’s disease M Argollo, G Fiorino, L Peyrin-Biroulet, S Danese Expert review of clinical immunology 14 (3), 179-189, 2018 | 11 | 2018 |
